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INTRODUCTION
Malaria is one of the most serious and widespread
health problem in many parts of the world, particularly in
Africa and Latin America with a high mortality rate. The
situation is further complicated by the spread of drug-
resistant parasites in many parts of the world where
Plasmodium falciparum is endemic. The multi-drug re-
sistance in P. falciparum is a major problem in many coun-
tries and the number of drugs available, effective and
affordable is very limited1. The malaria situation is ag-
gravated by the appearance of strains of P. falciparum
resistant to antimalarial drugs as well as by the resistance
of vector Anopheles mosquitoes to DDT and other insec-
ticides2.
As malaria vaccines remain problematic, chemo-
therapy is the most important weapon in the fight against
the disease3, 4. The antimalarial drugs including chloro-
quine, quinine, mefloquine and artemisinin are currently
used to prevent and treat human malaria. Part of the
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ABSTRACT
Background & objectives: The purpose of this study was to compare antimalarial activity of Artemisia turanica
Krasch as Iranian flora with current antimalarial drugs against Plasmodium berghei in vivo in mice.
Methods: Air-dried aerial parts of Iranian flora A. turanica were collected from Khorasan, northeastern Iran,
extracted with Et2O/MeOH/Petrol and defatted. Toxicity of herbal extracts was assessed on male NMRI mice,
and their antimalarial efficacy was compared with antimalarial drugs [artemether, chloroquine and sulfadoxine-
pyrimethamine (Fansidar)] on infected P. berghei animals. All the groups were investigated for parasitaemia,
body weight, hepatomegaly, splenomegaly and anemia. The significance of differences was determined by Analysis
of Variances (ANOVA) and Student’s t-test using Graph Pad Prism software.
Results: The inhibitory effects of A. turanica extract on early decline of P. berghei parasitaemia highlights its
antimalarial activity, however, this effect no longer can be observed in the late infection. This may be due to the
metabolic process of A. turanica crude extract by mice and reduction of its concentration in the body. Crude
extract of A. turanica represented its antisymptomatic effects by stabilization of body, liver and spleen weights.
Conclusion: This study confirmed antimalarial effects of A. turanica extracts against murine malaria
in vivo during early infection, however, there are more benefits on pathophysiological symptoms by this
medication.
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reason for the failure to control malaria, is the spread of
resistance to the first line antimalarial drugs, cross-resis-
tance between the limited number of drug families avail-
able, and some multidrug resistance5. Resistance has
emerged to all the classes of antimalarial drugs except
artemisinin, an endoperoxide antimalarial drug derived
as the active component of Artemisia annua, a herbal rem-
edy used in Chinese folk medicine for 2000 years
“qinghaosu”6–9. Artemisinin is a powerful antimalarial
drug with significant activities, against Plasmodium
strains which are resistant to chloroquine. It is a natural
product, which has the characteristics of high potency
against the parasite whilst possessing low toxicity during
treatment of malaria infections10–12.
The genus Artemisia (Asteraceae tribe Anthemideae)
belongs to the important family of medicinal and aro-
matic plants which comprises about 1000 genera and over
20,000 species13, 14. Within this family, Artemisia is in-
cluded into the trible Anthemideae and comprises itself
over 500 species. The 500 species of Artemisia are mainly J Vector Borne Dis 50, March 2013 52
found in Asia, Europe and North America. In all, 35
species of this genus are found in Iran, among those two
are dominating: A. melanolepis Boiss and A. kermanensis
Podl15, 16.
This genus including some Iranian species has been
studied chemically and present of monoterpenes16, ses-
quiterpenes17, 18, especially sesquiterpene lactones19, 20 and
essential oils21–25 were reported.
The extract of the aerial parts of A. diffusa Krasch ex
P. Poljakov collected in the Province of Khorassan (Iran)
afforded, in addition to several eudesmanolides, a new
type of sesquiterpene lactone (Tehranolide)20, with
anendoperoxide group that probably has the same effect
as the antimalarial agent artemisinin. The antimalarial
properties of the extract and the fraction which contains
sesquiterpene lactones including Tehranolide of the same
species (Artemisia diffusa)26. The results specifically in-
dicated the inhibitory effects of the A. diffusa crude ex-
tracts and the fraction which contains sesquiterpene lac-
tones including Tehranolide, on the developmental stages
of P. berghei by decreasing parasitaemia27.
The aerial parts of Iranian flora A. khorasanica were
collected at flowering stage from Khorassan Province,
northeastern Iran in 2008. Toxicity of herbal extracts was
assessed on naïve NMRI mice, and its antimalarial effi-
cacy was investigated on infected P. berghei animals. This
is the first application on A. khorassanica extract for treat-
ment of murine malaria. The herbal extract was success-
fully tested in vivo for its antiplasmodial activity through
artemisinin composition, which is widely used as a stan-
dard malaria treatment28.
The extract of the aerial parts of A. turanica Krasch
was collected from Esfarayen in the province of Khorasan,
northeastern Iran. The study especially examined the in-
hibitory effects of the extracts on the developmental stages
in vivo of P. berghei in mice. In the preliminary experi-
ments, the toxicity of the A. turanica extract was tested
and from the high doses that were tolerated without sig-
nificant overt mortality or signs of toxicity, it was esti-
mated that the extract of plant is of relating low toxicity.
The pharmacological and biochemical evaluation on
antimalarial effects of A. turanica and A. oliveriana on
P. berghei in vivo, showed that two extracts were effec-
tive against malarial agent29. Last study especially exam-
ined the inhibitory effects of the extracts on the develop-
mental stages in vivo of P. berghei in mice but in this
work, the extract of A. turanica was successfully tested
in vivo for its antimalarial activity and compared with
other current antimalarial drugs (artemether, chloroquine
and fansidar) which are widely used as a standard ma-
laria therapy.
MATERIAL & METHODS
 Plant material
The aerial parts of A. turanica, were collected from
Baam village, after Gahreman abad in Esfarayen, Prov-
ince of Khorasan, northeastern Iran, in 2011. Voucher
specimens have been deposited at the Herbarium of the
Research Institute of Forests and Rangelands (TARI),
Tehran, Iran.
Extraction
The aerial parts of A. turanica were air-dried at room
temperature and were then powdered. The herbs powder
(150 g) was extracted with Et2O/MeOH/Petrol (1:1:1) (2
× 250 ml) at room temperature for 48 h. Evaporation at
reduced pressure furnished crude extract (7 g), which was
suspended in EtOH (120 ml), diluted with water
(100 ml) and extracted successively with hexane (2 × 100
ml) and chloroform (2 × 100 ml). Evaporation of the
CHCl3 extract at reduced pressure furnished 4 g of resi-
due.
Animals
Male outbred NMRI mice, supplied by the Karaj
Laboratory Animal Unit, Pasteur Institute of Iran were
used in this study. The mice were housed at room tem-
perature (20–23°C) on a 12 h light and 12 h dark cycle,
with unlimited access to food and tap water. Experiments
with animals were done according to the ethical standards
formulated in the Declaration of Helsinki, and adequate
measures were taken to protect animals from pain or dis-
comfort. The study has been approved by the Institutional
Ethical Review Board (Ethical Committee of the Pasteur
Institute of Iran).
Malaria parasites
Plasmodium berghei NY strain was kindly donated
by Dr M.J. Dascombe from the School of Life Sciences,
University of Manchester, UK. Malaria parasite was main-
tained by blood passage in NMRI mice when active para-
sites were required; otherwise it was stored at –70°C in
Alserver’s solution (2.33% glucose, 0.525% NaCI and
1% sodium citrate in deionised water) and glycerol (9:1
parts by volume).
Inoculation of malaria parasites
Mice were inoculated (0.2 ml, i.v.) into a tail vein
with blood from a donor mouse (41% parasitaemia P.
berghei) diluted with 0.85% saline to contain 2×107
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Study on toxicity of herbal extracts on naive mice
Three different concentrations of herbal extracts (50,
5 and 0.05 mg/ml) were tested in addition to a control
(vehicle). All the animals were injected s.c. every day for
8 days with 100 µl solutions. Four groups of mice (n =
10) were investigated for assessment of pathology includ-
ing body weight, physiological activities, hepatomegaly
and splenomegaly to assess the toxicity of the extracts.
Antimalarial effects of herbal extract on Plasmodium
berghei infected mice
Animals were divided into five groups (n=10 mice/
group), namely a control (Drug vehicle), A. turanica ex-
tract, artemether, chloroquine and fansidar. All the groups
were infected with murine malaria parasite, P. berghei.
Artemisia turanica extract in 50 mg/ml concentration and
control (100 µl) were injected s.c. into control and test
groups respectively every day with 100 µl of solutions
for the period of 12 days after infection in malaria mice.
Artemether in 4 mg/kg concentration and chloroquine in
5 mg/kg concentration (100 µl) were injected i.m. every
day for 12 days after infection in malaria mice. Fansidar
in 25 mg/kg concentration (100 µl) were fed by gavage
every day for 12 days after infection in malaria mice. After
the injections period, five groups of mice (n=10 mice/
group), were investigated for antimalarial efficacy, de-
gree of parasitaemia, assessment of pathology including
body weight, physiological activities, hepatomegaly, sple-
nomegaly and anemia.
Parasitaemia was measured every other day by count-
ing Giemsa-stained blood smears from end tail cutting.
Diagnosis of anemia by measuring Hematocrit (Hct),
hepatomegaly, splenomegaly was measured last day. The
body weight was measured on first and last day.
Following toxicity assay, the highest dose of herbal
extract (50 mg/ml concentration) was selected to apply
for its antimalarial activity on male NMRI mice infected
with P. berghei.
Assessment of pathology
Parasitaemia
The clinical diagnosis was confirmed by laboratory
demonstration of the malaria parasite in the stained
smears. In all animals, parasitaemia was determined on
different days after infection using blood smears stained
with Giemsa stain (Sigma Chemical Co., USA). Parasit-
ized red blood cells (PRBC) were counted in five differ-
ent fields, each of approximately 200 cells. Results ex-
pressed as the mean percentage of erythrocytes containing
Giemsa positive bodies. Experiments were licensed un-
der the Animals (Scientific Procedures) Act 1986. In com-
pliance with the conditions of this license, infected ani-
mals were humanely killed at the onset of the terminal
phase of malaria (P. berghei NY) infection.
Assessment of degree of hepato/splenomegaly
Entire livers and spleens were removed during post-
mortem at the end of the experimental period from mice
after induction of terminal general anaesthesia by inhala-
tion of diethyl ether (Sigma Co., Germany). Organ wet
weights were measured and compared with controls as
indices for degree of hepatomegaly and splenomegaly.
Diagnosis of anemia by measuring hematocrit (Hct)
Hematocrit is a screening test to determine anemia.
The hematocrit measured manually by centrifugation. A
thin capillary tube called a microhematocrit tube is filled
with blood and sealed at the bottom. The tube is centri-
fuged at 10,000 RPM (revolutions per minute) for five
min. The RBCs have the greatest weight and are forced
to the bottom of the tube. The WBCs and platelets form a
thin layer, called the buffy coat, between the RBCs and
the plasma, and the liquid plasma rises to the top. The
height of the red cell column is measured as a percent of
the total blood column. The higher the column of red cells,
the higher the hematocrit.
RBCvolume % Hct = 100
RBCvolume + Plasma volume

Body weight
Body weight was measured initially and at different
times of experiment using a top pan balance (OHAUS
Scale Corp., USA).
Statistical analysis
Values are presented as the mean ± SEM for groups
of samples.
The significance of differences was determined by
analysis of variances (ANOVA) and Student’s t-test us-
ing Graph Pad Prism Software (GraphPad, San Diego,
California, USA) (*p<0.05, **p<0.01, p<0.001).
RESULTS
The results of toxicity assay in naïve mice indicated
no significant pathophysiological changes in hepatome-
galy and splenomegaly in test groups as compared with
those in control after injection of low, average and high
doses of A. turanica crude extracts. There was a little
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with high dose of herbal crude, emphasising the anti-
symptomatic effects of A. turanica.
As shown, no toxicity was observed in vivo even with
high dose of A. turanica total extract. Pathophysiological
signs including body weight, hepatomegaly, and splenom-
egaly represented no side effects of total extract (Fig. 1).
The clinical diagnosis of P. berghei infection was
confirmed by laboratory demonstration of the malaria
parasite in the stained smears. Parasitaemia was deter-
mined using blood smears stained with Giemsa stain from
mice (Fig. 2). The observations specifically indicated the
inhibitory effects of A. turanica extract on the early dev-
elopmental stages of P. berghei by decreasing parasitae-
mia (p <0.01). This may suggest that the active constitu-
ents in the herbal extract may be toxic for P. berghei,
thereby inhibiting their development to the erythrocytic
stages (Fig. 3).
No pathophysiological changes including body
weight, hepatomegaly and splenomegaly were detected
in control and malarial groups as induction markers for
toxicity after injection of crude extract of A. turanica in
malarial infected animals (Fig. 4).
DISCUSSION
 Although, malaria is still one of the most common
infectious diseases and an enormous public health prob-
lem and as malaria vaccines remain problematic, chemo-
therapy is the most important weapon against the disease.
Fig. 2: Plasmodium berghei blood-stage forms in Giemsa stained
smears from mice.
Fig. 3: Percentage of parasitaemia in smears from blood of malarial
mice test, A. turanica crude extract; control and antimalarial
drugs (n=10 mice/day/group, Student’s t-test, **p <0.01).
Fig. 1: Toxicity assay and pathophysiological changes induced by
A. turanica crude extract in naive animals. Pathophysiological
changes including body weight (a); hepatomegaly (b); and
splenomegaly (c); were evaluated in control and test groups
as toxicity assay induced by injection of low, average and
high doses of A. turanica crude extract (n=10, *p <0.05,
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The current antimalarial drugs have their own problems
to prevent and treat human malaria.
The results of this study indicated no toxicity in naïve
mice with even high dose of A. turanica crude extracts,
which confirm its lowest effects. Although, the inhibi-
tory effects of the A. turanica extract on the early decline
of P. berghei parasitaemia highlight its antimalarial ac-
tivity, but effect no longer can be observed in the late
infection. This may be due to the metabolic process of A.
turanica crude extract by mice and reduction of its con-
centration in body. Malaria parasite actually decreases
body weight and increases hepatomegaly and splenom-
egaly. Crude extract of A. turanica represented its anti-
symptomatic effects by stabilization of body, liver and
spleen weights.
This is the first report on comparison of in vivo anti-
malarial activity of Iranian flora A. turanica crude ex-
tract and other antimalarial drugs (artemether, chloroquine
and fansidar) against P. berghei in mice model.
The herbal extract was successfully tested in vivo for
its antimalarial activity and compared with other current
antimalarial drugs (artemether, chloroquine and fansidar)
which is widely used as a standard malaria therapy. Al-
though, this study confirmed antimalarial effects of A.
turanica extracts against murine malaria in vivo during
early infection, however, there are more efficacies on
pathophysiological symptoms by this medication. As it
shown in hepatomegaly diagram, A. turanica extract de-
creases the anemia better than others. These observations
provide the basis for the traditional use of this herb in
treatment of malaria disease. The route of inoculation is
an important factor to determine herbal efficacy. More
investigations on different Plasmodia and animal hosts
are needed to clarify antimalarial activity of Iranian flora
A. turanica and analysis of its natural components more
effectively.
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